

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Supplementary Material

Supplementary Table 1. Detected molecular aberrations, affected pathways and treatment outcomes

Molecular Aberration	Affected pathway	PR	SD > 12 months	SD < 12 months	PD	Not evaluable for response
<i>APC</i> A2122_C2123insA	Wnt		1			
<i>BRAF</i> V600E	MAPK				1	
<i>GNAQ</i> Q209P	MAPK				1	
<i>KIT</i> M541L ¹ , <i>KDR</i> C482R ¹	KIT, VEGFR			1		
<i>KIT</i> M541L ¹	KIT	1	1			
<i>KRAS</i> G12C	MAPK			1		
<i>KRAS</i> G12D	MAPK				1	
<i>KRAS</i> G12S	MAPK					1
<i>KRAS</i> G13D	MAPK			1		
<i>MET</i> N375S	MET			1		
<i>NF1</i> R1241*, <i>BAP1</i> truncation, <i>CTNNB1</i> N387K	MAPK, BAP, Wnt				1	
<i>NRAS</i> Q61K	MAPK				1	
<i>NRAS</i> Q61R	MAPK			1	1	1
<i>PIK3CA</i> H1047L	PI3K					1
<i>PIK3CA</i> H1047R, <i>CTNNB1</i> S37C, <i>PTPRD</i> S1845fs*2	PI3K, Wnt, STAT3			1		
<i>PTEN</i> R335*, <i>CDKN2A/B</i> loss	PI3K, CDK			1		
<i>TP53</i> G245S	TP53					1
<i>TP53</i> L194F	TP53			1		
<i>TP53</i> R175H	TP53				2	
<i>TSC2</i> loss, <i>XPO1</i> E571K	mTOR, XPO1	1				
No aberration				8	13	3
Not done				7	14	2

Abbreviations: PR, partial response; SD, stable disease; PD, progressive disease

¹Possible germline polymorphism